PD-1/PD-L1 inhibitors primarily act within the tumor microenvironment to restore T-cell effector functions, while CTLA-4 inhibitors enhance the activation of naïve T-cells in lymphoid tissues. This evidence concerns the gene CD274 and neoplasm.